(VIANEWS) – MFA Financial (MFA), Genmab (GMAB), Fabrinet Ordinary Shares (FN) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. MFA Financial (MFA)
20.3% sales growth and 4.12% return on equity
MFA Financial, Inc., together with its subsidiaries, operates as a real estate investment trust in the United States. The company invests in residential mortgage assets, including non-agency mortgage-backed securities, agency MBS, and credit risk transfer securities; residential whole loans, including purchased performing loans, purchased credit deteriorated, and non-performing loans; and mortgage servicing rights related assets. MFA Financial, Inc. was incorporated in 1997 and is based in New York, New York.
Earnings Per Share
As for profitability, MFA Financial has a trailing twelve months EPS of $0.46.
PE Ratio
MFA Financial has a trailing twelve months price to earnings ratio of 23.39. Meaning, the purchaser of the share is investing $23.39 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.12%.
2. Genmab (GMAB)
16.6% sales growth and 14.78% return on equity
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Earnings Per Share
As for profitability, Genmab has a trailing twelve months EPS of $0.96.
PE Ratio
Genmab has a trailing twelve months price to earnings ratio of 30.48. Meaning, the purchaser of the share is investing $30.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.78%.
Yearly Top and Bottom Value
Genmab’s stock is valued at $29.26 at 20:22 EST, way below its 52-week high of $42.99 and way higher than its 52-week low of $26.32.
Volume
Today’s last reported volume for Genmab is 412206 which is 34.38% below its average volume of 628181.
Revenue Growth
Year-on-year quarterly revenue growth declined by 8.9%, now sitting on 16.47B for the twelve trailing months.
Previous days news about Genmab(GMAB)
- According to Zacks on Friday, 26 April, "The company recorded sales worth $27 million from the recently launched lymphoma drug Epkinly/Tepkinly, which is marketed in partnership with Genmab (GMAB Quick QuoteGMAB – Free Report) . "
3. Fabrinet Ordinary Shares (FN)
12.3% sales growth and 16.98% return on equity
Fabrinet provides optical packaging and precision optical, electro-mechanical, and electronic manufacturing services in North America, the Asia-Pacific, and Europe. The company offers a range of advanced optical and electro-mechanical capabilities in the manufacturing process, including process design and engineering, supply chain management, manufacturing, printed circuit board assembly, advanced packaging, integration, final assembly, and testing. Its products include switching products, including reconfigurable optical add-drop multiplexers, optical amplifiers, modulators, and other optical components and modules that enable network managers to route voice, video, and data communications traffic through fiber optic cables at various wavelengths, speeds, and over various distances. The company's products also comprise tunable lasers, transceivers, and transponders; and active optical cables, which provide high-speed interconnect capabilities for data centers and computing clusters, as well as Infiniband, Ethernet, fiber channel, and optical backplane connectivity. In addition, it provides solid state, diode-pumped, gas, and fiber lasers used in semiconductor processing, biotechnology and medical device, metrology, and material processing industries; and differential pressure, micro-gyro, fuel, and other sensors used in automobiles, as well as non-contact temperature measurement sensors for the medical industry. Further, the company designs and fabricates application-specific crystals, lenses, prisms, mirrors, laser components, and substrates; and other custom and standard borosilicate, clear fused quartz, and synthetic fused silica glass products. It serves original equipment manufacturers of optical communication components, modules and sub-systems, industrial lasers, automotive components, medical devices, and sensors. The company was incorporated in 1999 and is based in George Town, the Cayman Islands.
Earnings Per Share
As for profitability, Fabrinet Ordinary Shares has a trailing twelve months EPS of $6.93.
PE Ratio
Fabrinet Ordinary Shares has a trailing twelve months price to earnings ratio of 23.73. Meaning, the purchaser of the share is investing $23.73 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.98%.
Volume
Today’s last reported volume for Fabrinet Ordinary Shares is 145263 which is 70.87% below its average volume of 498732.
Yearly Top and Bottom Value
Fabrinet Ordinary Shares’s stock is valued at $164.45 at 20:22 EST, way under its 52-week high of $229.02 and way higher than its 52-week low of $90.19.
Moving Average
Fabrinet Ordinary Shares’s worth is way below its 50-day moving average of $194.98 and under its 200-day moving average of $170.99.
4. Garmin (GRMN)
9.2% sales growth and 19.52% return on equity
Garmin Ltd. designs, develops, manufactures, markets, and distributes a range of wireless devices worldwide. Its Fitness segment offers running and multi-sport watches; cycling products; smartwatch devices; scales and monitors; and fitness accessories. This segment also provides Garmin Connect and Garmin Connect Mobile, which are web and mobile platforms where users can track and analyze their fitness, activities and workouts, and wellness data; and Connect IQ, an application development platform. The company's Outdoor segment offers adventure watches, outdoor handhelds and satellite communicators, golf devices, consumer automotive devices, and dog devices, as well as InReach and Gramin response communication device. Its Aviation segment designs, manufactures, and markets various aircraft avionics solutions, including integrated flight decks, electronic flight displays and instrumentation, navigation and communication products, automatic flight control systems and safety-enhancing technologies, audio control systems, engine indication systems, traffic awareness and avoidance solutions, ADS-B and transponders, weather information and avoidance solutions, datalink and connectivity solutions, and various services. The company's Marine segment provides chartplotters and multi-function displays, cartography products, fishfinders, sonar products, autopilot systems, radars, compliant instrument displays and sensors, VHF communication radios, handhelds and wearable devices, sailing products, audio products and accessories, digital switching products, and trolling motors. Its Auto segment offers embedded domain controllers and infotainment units; and software, map database, cameras, wearables, and automotive solutions. The company sells its products through independent retailers, dealers, distributors, installation and repair shops, and original equipment manufacturers, as well as online webshop. Garmin Ltd. was founded in 1989 and is based in Schaffhausen, Switzerland.
Earnings Per Share
As for profitability, Garmin has a trailing twelve months EPS of $6.71.
PE Ratio
Garmin has a trailing twelve months price to earnings ratio of 21.33. Meaning, the purchaser of the share is investing $21.33 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.52%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13.5%, now sitting on 5.23B for the twelve trailing months.
5. Zoetis (ZTS)
7.5% sales growth and 49.82% return on equity
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
Earnings Per Share
As for profitability, Zoetis has a trailing twelve months EPS of $5.08.
PE Ratio
Zoetis has a trailing twelve months price to earnings ratio of 29.52. Meaning, the purchaser of the share is investing $29.52 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 49.82%.
Previous days news about Zoetis(ZTS)
- Wall street analysts look bullish on zoetis (zts): should you buy?. According to Zacks on Friday, 26 April, "Check price target & stock forecast for Zoetis here>>>While the ABR calls for buying Zoetis, it may not be wise to make an investment decision solely based on this information. ", "Let’s take a look at what these Wall Street heavyweights have to say about Zoetis (ZTS Quick QuoteZTS – Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage."
